Akums Drugs saw its shares slip more than 3% after the company posted a subdued set of numbers for the September quarter. The latest financials indicate pressure on profitability, with both operating performance and bottom line declining year-on-year.
For Q2, the company reported revenue of ₹1,018 crore, down 1.5% from ₹1,033 crore in the same period last year. The dip in topline combined with higher costs pulled down operating performance as well. EBITDA fell 22.1% to ₹94.4 crore, compared with ₹121 crore a year earlier. Correspondingly, EBITDA margin narrowed to 9.3% from 11.7%.
The decline was sharper on the net profit front. Akums Drugs posted a profit of ₹40.7 crore, a significant 37.6% drop from ₹65.2 crore last year.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
